Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) @biogerontology · 02 Sep 2026
@biogerontology Uhh it's an SGLT2 inhibitor. We already know it treats heart failure. Positive phase 3 trials, in guidelines, the whole deal. Chronic kidney disease and diabetes too. They don't cause much weight loss though. Hope the pandaomics finds something.
118Views
2Likes
0Reposts
1Replies
0Quotes
0Bookmarks
Is that a lot?
0.18×vs this author's median664 views is typical
27Percentile for this authorof 11 recent posts
0.05×vs 10K–100K median2 578 views is typical
0.30%Reachviews ÷ followers
2.54%Engagement rateof viewers reacted